Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Update

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 47,700 shares, a decrease of 77.2% from the January 15th total of 209,500 shares. Based on an average trading volume of 507,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.7% of the company’s shares are short sold.

Sol-Gel Technologies Stock Performance

SLGL stock traded down $0.02 during trading on Wednesday, hitting $0.60. 59,900 shares of the company traded hands, compared to its average volume of 270,157. The firm has a market capitalization of $16.80 million, a PE ratio of -1.77 and a beta of 1.31. Sol-Gel Technologies has a 1 year low of $0.33 and a 1 year high of $1.65. The company has a 50-day moving average of $0.85 and a 200-day moving average of $0.68.

Institutional Investors Weigh In On Sol-Gel Technologies

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Raymond James Financial Inc. acquired a new position in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned 0.39% of Sol-Gel Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 26.18% of the company’s stock.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.